DelveInsight’s, “Basal Cell Nevus Syndrome Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Basal Cell Nevus Syndrome pipeline landscape. It covers the Basal Cell Nevus Syndrome pipeline drug profiles, including Basal Cell Nevus Syndrome clinical trials and nonclinical stage products. It also covers the Basal Cell Nevus Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Basal Cell Nevus Syndrome Pipeline treatment landscape of the report, click here @ Basal Cell Nevus Syndrome Pipeline Outlook
Key Takeaways from the Basal Cell Nevus Syndrome Pipeline Report
For further information, refer to the detailed Basal Cell Nevus Syndrome Unmet Needs, Basal Cell Nevus Syndrome Market Drivers, and Basal Cell Nevus Syndrome Market Barriers, click here for Basal Cell Nevus Syndrome Ongoing Clinical Trial Analysis
Basal Cell Nevus Syndrome Overview
The nevoid basal cell carcinoma syndrome (NBCCS) is a rare, complex genetic disorder characterized by a wide variety of developmental abnormalities and a predisposition to developing certain forms of cancer, particularly a type of skin cancer known as basal cell carcinoma.
Request a sample and discover the recent advances in Basal Cell Nevus Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Basal Cell Nevus Syndrome Treatment Landscape
Basal Cell Nevus Syndrome Emerging Drugs
PellePharm is focused on developing patidegib, an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. As of November 2018, PellePharm and LEO Pharma entered into a strategic collaboration to address the unmet medical needs for rare skin conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (HF-BCC). PellePharm has received both Orphan Drug Designation and Breakthrough Therapy Designation for Patidegib Topical Gel in Gorlin Syndrome from the FDA, as well as Orphan Drug Designation in Gorlin Syndrome from EMA’s Committee for Orphan Medicinal Products in the EU.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Basal cell nevus syndrome.
Vismodegib is an experimental, oral smoothened antagonist and thus inhibits hedgehog pathway. It is under Phase II development for Basal cell nevus syndrome.
Dive deep into rich insights for drugs for Basal Cell Nevus Syndrome Market Drivers and Basal Cell Nevus Syndrome Market Barriers, click here @ Basal Cell Nevus Syndrome Unmet Needs and Analyst Views
Basal Cell Nevus Syndrome Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Basal Cell Carcinoma. The companies which have their Basal Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.
Scope of the Basal Cell Nevus Syndrome Pipeline Report
Got Queries? Find out the related information on Basal Cell Nevus Syndrome Mergers and acquisitions, Basal Cell Nevus Syndrome Licensing Activities @ Basal Cell Nevus Syndrome Emerging Drugs, and Recent Trends
Table of Content
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services